Clinical Trial Update: A RCT to Assess the Performance of CytoSorb for Shock Reversal in Patients With Vasoplegic Septic Shock [NA]

View source ↗

Summary

The randomized trial evaluating CytoSorb for shock reversal in vasoplegic septic shock has been suspended.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Septic Shock

Drugs mentioned

• CytoSorb

Snippet

Sponsor: CytoSorbents Europe GmbH | Conditions: Septic Shock | NA | Status: SUSPENDED